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Online measurement of drug concentrations in patient’s breath is a promising approach for individualized
dosage. A direct transfer from breath- to blood-concentrations is not possible. Measured exhaled
concentrations are following the blood-concentration with a delay in non-steady-state situations. Therefore,
it is necessary to integrate the breath-concentration into a pharmacological model. Two different
approaches for pharmacokinetic modelling are presented. Usually a 3-compartment model is used for
pharmacokinetic calculations of blood concentrations. This 3-compartment model is extended with a
2-compartment model based on the first compartment of the 3-compartment model and a new lung
compartment. The second approach is to calculate a time delay of changes in the concentration of the first
compartment to describe the lung-concentration. Exemplarily both approaches are used for modelling of
exhaled propofol. Based on time series of exhaled propofol measurements using an
ion-mobility-spectrometer every minute for 346 min a correlation of calculated plasma and the breath
concentration was used for modelling to deliver R250.99 interdependencies. Including the time delay
modelling approach the new compartment coefficient ke0lung was calculated to ke0lung50.27 min21 with
R250.96. The describedmodels are not limited to propofol. They could be used for any kind of drugs, which
are measurable in patient’s breath.
I
n medicine, drug dosing is usually adapted to patient’s weight. However, the blood concentration of medica-
tions varies considerably between different individuals. The blood concentration depends on the liberation,
absorption, distribution, metabolism and the excretion of the drug. These factors are influenced by normal
variability of the individual, genetic influences particularly in cytochrome P450 system and organ dysfunctions.
These relationships are described as pharmacokinetics (PK).
Different compartment1 and non-compartment PK models e.g. physiological models2 are used to calculate
plasma or effect concentrations of drugs. These models are based on normal population PK data sets. However,
the concentrations are only calculated and the difference to the real drug blood concentration could be substan-
tially3. The measurement of blood concentration e.g. by High-Performance Liquid Chromatography (HPLC) is
expensive, complex and has a time delay of several hours. In clinical practise the measurement of blood con-
centrations is only performed for a few drugs4.
Therefore, a new promising approach is the online measurement of drug concentrations in patient’s breath5.
Until now, the number of drugs which were detected in patient’s breath is limited: e.g. methadone6, propofol7,
valproic acid8.
Actually, different methods are under consideration, including mass spectrometry, ion mobility spectrometry
and chemical sensors. In the present paper, we will not focus on the experimental details, conditions, advantages
and disadvantages of the different methods. The starting condition is, that such measurements can be carried out
and time series of breath concentration values are available within short time intervals. Acceptable would be the
range of one value per minute of exhaled breath concentration, with a total analysis time in the same range of 1
minute. Consequently, one value each minute with 1 minute retarding will be considered as provided by an
experimental breath analysis method.
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However, a direct transfer between breath concentration and
blood concentration is not possible and leads to poor correlation
values, because the diffusion of drugs through the capillary wall of
the alveoli takes time. If the drugs blood concentration increases or
decreases the exhaled concentration follows with a time delay9.
Classically the diffusion of a drug fromblood through the lung into
air is described by the blood/gas partition coefficient (Ostwald
Coefficient). This coefficient is defined as the ratio of the concentra-
tion in blood to the concentration in gas that is in contact with that
blood when the partial pressure in both compartments is at equilib-
rium. It is thus a dimensionless number. The higher the blood/gas
partition coefficient, the more soluble is the anaesthetic in blood
compared to air and the more it binds to lipids and proteins in the
blood. If an anaesthetic has a high Ostwald coefficient, then a large
amount of it will have to be taken up in the body’s blood before being
passed on to the fatty (lipid) tissues of the brain where it can exert its
effect10.
The blood/gas partition coefficient is widely used for the PK
description of volatile anaesthetics10. However, for PK modelling
the coefficient could only be used if the partial pressure in both
compartments is at equilibrium. Depending on the drug it could take
several hours to reach this steady state. Therefore, the introduction of
breath concentrations measured within time series needs a model to
include the concentration values measured in breath without the
precondition of compartments within equilibrium.
To overcome the precondition of equilibrium, we would like to
demonstrate in this manuscript two different PK modelling
approaches to handle the drug breath concentrations. The calcula-
tions are performed on the basis of concentration data of the mea-
surements of a patient, who received the intravenous anaesthetic
propofol. The propofol breath concentration was measured by a
modified ion mobility spectrometer combined with a multi-
capillary-column (P-IMS)11, which delivers one peak analysis every
minute with 1 minute total analysis time including sampling of
10 mL exhaled breath. It should be noted, that the presented models
are not specific for propofol. In principle, the mathematical descrip-
tions could also be used for other drugs.
Methods
Clinical measurements.With approval of the local Ethics Committee (A¨rztekammer
des Saarlandes, Saarbru¨cken, Germany) and written informed consent an adult
patient scheduled for an abdominal surgical procedure was studied. The patient
received propofol and remifentanil (opioid) as a target controlled infusion (TCI). The
concept of TCI is to estimates calculated plasma and effect site concentrations based
on pharmacokinetic 3 compartment model12.
The breath concentration values were measured using an ion mobility spectro-
meter type BioScout (B&S Analytik GmbH, Dortmund, Germany), with the internal
Multi-capillary-column (MCC) adjusted to 90uC to reach a retention time of propofol
on the MCC (type OV-5, Multichrom, Novosibirsk, Russia) of about 20 s. A total
volume of 10 mL was taken on the MCC. For further details considering the method
see11, for the experimental setup see13. Samples of exhaled air were automatically taken
every minute by the P-IMS.
A typical pharmacokinetic model including 3 compartments is shown in Figure 1.
Here, V1 represents the central blood compartment, the other 2 compartments
named V2 and V3 are considered as an additional fast and another slowmetabolizing
compartment. Therefore, the incoming intravenous drug (i.v.) will go with the
reaction coefficient k10 out of the body (elimination) and with e.g. k13 from V1 to V3
and k31 fromV3 back to V1, respectively. The clearance of the central compartment is
described as V1 * k10 and the concentration in compartment V3 is represented by the
value V3 5 V1 * k13/k31. Thus, the clearance 2 is V2 * K21.
For the administration of propofol we used the Marsh data set14 with a constant
target concentration of 3 mg/ml in compartment V1. The corresponding values of V1
and the reaction coefficients are shown in Table 1. Here, following to the Marsh
model, V1 is calculated with the weight of the patient multiplied with 0.228 (Table 1).
The major disadvantage of TCI is that the concentrations are only calculated and
may have a deviation of about 25%3 in healthy patients. The remifentanil target
concentration (Minto, plasma mode)15 was adjusted to clinical needs.
Pharmacokinetic modeling. Plotting the exhaled propofol concentration versus the
calculated propofol plasma concentration revealed a hysteresis loop (see below).
Therefore, it is necessary to include the measured propofol concentration into a
pharmacokinetic model.
Two different approaches for kinetic modelling were tried. First the 3-compart-
ment model was extended. We calculated an additional 2-compartment model based
on the first compartment of the Marsh model and a new lung compartment VLung
(Fig. 2).
For the relationship between exhaled propofol concentration and the respective
propofol lung concentration values a polynomial second order was used. VLung,
ClLung and the parameters of the polynomial second order were estimated using
nonlinear regression with ordinary least squares.
The computations were performed on a spreadsheet using the Excel 2010 software
program (Microsoft). The parameters were optimized tomaximise R2 using the Solver
tool within Excel.
The second approach was to calculate a time delay of the plasma concentration
dependent to the measurements of exhaled propofol concentrations as a first order
model (Fig. 3). The computation was performed in the same way as described above.
Concentrations measured with the IMS are given as intensities in volt. Usually
concentrations in this range are given as parts per billion [ppb]. The transfer from volt
to ppb was performed with a calibration curve. Therefore, the modelling of both
Figure 1 | Three compartment pharmacokinetic model. KXX5 rate constants for metabolism and elimination, V15 Volume of central compartment/
blood concentration, V2 5 V1*k12/k21, V3 5 V1*k13/k31, Elimination clearance5 V1*k10, Clearance 25 V2*k21, Clearance 35 V3*k31.
Table 1 | Marsh data set14 (m is the weight of the patient expressed
in kg)
V1 0,228*m [kg]
k10 0,1190
k12 0,1140
k21 0,0550
k13 0,0419
k31 0,0033
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approaches was done two times for volt and ppb. A difference occurs due to the non-
linear response of the ion mobility spectrometer within the calibration curve.
Results
The P-IMS was tested in patients under clinical conditions in the opera-
tion room. To demonstrate the mathematical PK/PD modeling
approaches data from one patient were used. The duration of this
measurement was 346 min.We were able to perform onemeasurement
each minute. There was no technical failure of the P-IMS hardware or
software. During induction of anaesthesia the exhaled propofol concen-
tration increased with a time delay compared to the TCI plasma con-
centration. During themaintenance of anaesthesia, the exhaled propofol
concentration increased continuously. The propofol TCI target plasma
concentration was set stable at 3 mg/ml. At the end of the surgical
procedure the propofol TCI administration was stopped. The exhaled
propofol concentration decreased with a small time delay (Fig. 4).
PK-Modeling. Plotting the propofol breath concentration peak
intensity [volt] a) or [ppb] b) versus calculated propofol plasma
concentration revealed a hysteresis loop (Fig. 5).
Figure 5 indicates that a direct correlation analysis between plasma
concentrations and exhaled concentrations is not useful. These cal-
culations lead to poor R2 values (R250,32 [volt]; R250,41 [ppb]).
Propofol lung compartment concentration. The hysteresis loop
collapsed by introduction of the propofol lung compartment con-
centration or a time delay of the propofol plasma concentration
(Fig. 6/Fig. 7).
Using themeasured breath concentration in ppb the propofol lung
compartment of this individual patient could be described by a
volume of 17 L and a clearance of 3,75 L/min. The rate constants
were k1L50,209 min21 and kL150,138 min21. Using these para-
meters for calculation the lung compartment concentration yielded
Figure 2 | 3-compartment pharmacokinetic model extended with an additional lung compartment with a volume (VLung) and clearance (ClLung).
LCC 5 (k1L*PPCO-kL1*LCCO)1LCCO. LCC5 Lung compartment concentration, k1L 5 Cllung/V1, PPCO 5 Previous Propofol plasma
concentration, kL1 5 Vlung/Cllung, LCCO 5 Previous lung compartment concentration, V1 5 Volume first compartment marsh model (50,228*
patient weight m [kg]). VLung 5 Volume lung compartment, ClLung 5 Clearance lung compartment.
Figure 3 | Three compartment pharmacokinetic model the propofol lung concentration is calculated from the blood concentration with a time
delay. LCC 5 (PPC1 (LCCO-PPC))*exp(-ke0lung), PPC 5 Propofol plasma concentration, ke0lung 5 First-order rate constant determining the
equilibration between plasma, and lung concentration.
www.nature.com/scientificreports
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into a correlation coefficient of R250.99 (Fig. 6b). The polynomial
second order is given by:
y525.9*x2 1 9.23*x 1 0,
where y is the lung compartment concentration and x the propofol
breath concentration.
The correlation value is lower using the original intensity values
given in volt (R250.87)(Fig. 6a).
y5212.6*x2 1 15.57*x 1 0,
where y is the lung compartment concentration and x the propofol
peak intensity.
Time delay of the propofol plasma concentration. The time delay
pharmacokinetic modeling approach results into a lower correlation
coefficient R250.96 than using an additional compartment for
describing the lung propofol concentration (Fig. 7).
The correlation between the model and measurements in ppb is
R250.96 (Fig. 7b).
y524.2*x2 1 7.14*x 1 0,
where y is the lung compartment concentration and x the propofol
concentration.
The propofol lung plasma time delay concentration of this indi-
vidual patient was calculated with a first- order rate constant deter-
mining the equilibration between plasma and lung concentration
ke0lung 5 0.27 min21.
The correlation value is lower using the original intensity values
given as peak height measured in volt (R2 5 0.82) (Fig. 7a).
Figure 4 | Time course. Time course of the calculated propofol TCI concentration (blue line) and the measured P-IMS breath concentration (red line
concentration [ppb], green line peak height [volt]) over 346 min.
Figure 5 | Hysteresis loop between plasma concentration and breath concentration. Calculated propofol plasma concentration versus breath
concentration measured by the P-IMS (a) green dots: peak height; [volt]; (b) red dots: concentration [ppb].
www.nature.com/scientificreports
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y527.7*x2 1 9.64*x 1 0,
where y is the lung compartment concentration and x the propofol
peak intensity.
Discussion
In this manuscript two different pharmacological models are pre-
sented for the description of the pharmacokinetic of exhaled drug
concentrations. The calculations were exemplarily performed for
propofol, an intravenous anaesthetic widely used in clinical practice.
The exhaled propofol concentration was measured with a modified
MCC/IMS (P-IMS).
Under clinical conditions it is not possible tomeasure the propofol
blood concentration online. Therefore, computer-assisted infusion
pumps (Target controlled infusion (TCI)) were developed to cal-
culate the propofol blood concentration based on the demographic
patient data and the dosage12. A 3-compartment pharmacokinetic
model is used for the calculation of the blood concentration. This
blood or plasma concentration is given in the first compartment V1.
Our first PK modeling approach is to extend this 3-compartment
model for another 2-compartmentmodel. The first compartment V1
is used parallel for both models. The second compartment of the 2-
compartment model represents the lung compartment. The lung
compartment has a volume (VLung). The volume is given in liters
(L). The value is a virtual volume of distribution and not physiologic-
ally. The second parameter is the clearance of the compartment given
in L/min (ClLung). Both values are used to calculate rate constants
for metabolism and elimination. We have named these constants as
k1L and kL1. kL1 is the deviation of the volume of the lung com-
partment and clearance of the lung compartment. k1L is required to
balance the drug concentration between the lung compartment and
the blood compartment. This PK approach has to be used if the drug
is metabolized by the lung or if the drug accumulates in the lung. If
there a metabolism of the drug in the lung the clearance value is
positive. The clearance value is negative, if an accumulation is pre-
Figure 6 | Propofol lung compartment concentration.The dots are themeasured propofol concentration (a) green dots: peak height [volt]), (b) red dots:
concentration [ppb] versus the propofol lung compartment concentration in mg/ml. The blue line is the polynomial second order.
Figure 7 | Time delay of the propofol plasma concentration. The dots are the measured propofol concentration (a) green dots: peak height [V], (b) red
dots: concentration [ppb] versus the propofol lung plasma time delay concentration in mg/ml. The blue line is the polynomial second order.
www.nature.com/scientificreports
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sent. For propofol there are some publications from animal studies,
hypothesizing that propofol is metabolized by the lung16.
Our second approach could be used, if there is only a time delay
between changes of the drug concentration and exhaled concentra-
tions. This PK model excludes changes of the concentration by the
lung itself. The equilibration between plasma and lung concentration
is described by a first-order rate constant (ke0). The ke0 value
describes the time delay between changes of the blood concentration
of anaesthetics and their effect at the brain measured with the EEG17.
The transition of anaesthetics across the blood–brain barrier needs a
certain time. The effects of anaesthetics on the brain can bemeasured
with an EEG monitor18.
Then this method was transferred to describe the time delay
between changes of the measured end-tidal concentration of volatile
anaesthetics and the EEG effect19. Equilibration between end-tidal
and brain concentrations of volatile anaesthetics is reached after a
time delay that is substance-specific and called hysteresis, i.e. the
delay between the maximum plasma concentration and the max-
imum EEG effect. In PK/PD models this hysteresis is considered
by inclusion of a fictitious compartment, the so called ‘‘effect
compartment’’.
We used thismathematical procedure now to describe a time delay
between changes of the drug blood concentrations and the exhaled
concentrations. To distinguish between the ‘‘traditional’’ ke0 value10
and the new approach we introduced the term ke0lung. In generally,
the higher the value of ke0lung, the shorter the time of equilibration
between exhaled and blood concentration.
In our sample calculation for propofol bothmethods were suitable
to describe the pharmacokinetic of the exhaled propofol
concentration.
We used a polynomial of second order as a function for the PK
model. For other drugs or biomarkers a linear correlation analysis
could be sufficient. In other cases it could be necessary to choose a
polynomial of a higher degree or a different mathematical model.
The calculations were performed for one individual patient. For
one patient PKmodeling could be done within Excel using the solver
tool to optimize the correlation between the pharmacology model
and measurements. For further analysis data of several patients in
one step a Bayesian probability calculation is necessary19. The pre-
sented PKmodelingmethods are suitable for the continuous applica-
tion of a drug. In principle they could also be used for a single bolus
application.
The pharmacological principles demonstrated for propofol in this
manuscript could be transferred to other medications. For propofol,
further studies including measured propofol blood concentrations
are necessary to build a PK model, which could be transferred into
clinical practice.
Online measurement of drug concentrations in patient’s breath is
a new promising approach for individualized dosage of medications.
Unfortunately there is no direct correlation between exhaled and
blood concentration of the drug. Therefore pharmacokinetic mod-
elling is necessary for research and clinical practice.
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